Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma. Issue 7 (8th March 2022)

• Record Type: Journal Article
• Authors: Gentille, Cesar; Sarfraz, Humaira; Joshi, Jitesh; Randhawa, Jasleen; Shah, Shilpan; Pingali, Sai Ravi
• Is Part Of: Cancer reports. Volume 5:Issue 7(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-03-08
• Subjects: brentuximab vedotin -- ICE -- relapsed/refractory PTCL -- romidepsin -- salvage chemotherapy; Cancer -- Periodicals; 616.994005
• DOI: 10.1002/cnr2.1581
• Languages: English
• ISSNs: 2573-8348

Abstract

Abstract: Background: Relapsed/refractory peripheral T‐cell lymphoma (R/R PTCL) has a poor prognosis. Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL. Aim: We report outcomes of Bv‐ICE in CD30 (+) and Ro‐ICE in CD30 (−) R/R PTCL treated in "Blinded for peer review" Cancer Center. Methods and Results: We retrospectively identified R/R PTCL patients treated with BV‐ICE or romidepsin‐ICE from May 2016 to September 2019. Out of 13 R/R PTCL patients, 6 were treated with Bv‐ICE and 7 with Ro‐ICE. Bv‐ICE had an overall response rate (ORR) of 66.7%, with all the patients achieving a complete response. ORR was 71.4% for Ro‐ICE with 57.1% of patients achieving a complete response. Two patients treated with Bv‐ICE and three treated with Ro‐ICE received transplantation. Conclusion: In our experience, treatment with Bv‐ICE and Ro‐ICE based on CD30 positivity is feasible and effective to treat patients with R/R PTCL.